XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2023     8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 $ 48,148 $ 8 $ 576,971 $ (42) $ (528,081) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,401) (5,401)       (5,401)    
Share-based compensation (in shares)     157,000          
Share-based compensation 312 312   312        
Unrealized loss on marketable securities (13) (13)     (13)      
Foreign currency translation adjustment (49) (49)     (49)      
Common stock, ending balance (in shares) at Mar. 31, 2024     8,308,000          
Ending balance at Mar. 31, 2024 $ 42,743 42,997 $ 8 577,283 (104) (533,482) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2024 8,408,844   8,410,000          
Beginning balance at Dec. 31, 2024 $ 29,317 29,571 $ 8 578,418 (81) (548,066) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,724) (4,724)       (4,724)    
Share-based compensation (in shares)     151,000          
Share-based compensation 286 286   286        
Net proceeds from issuances of common stock (in shares)     56,000          
Net proceeds from issuances of common stock $ 212 212 $ 1 211        
Proceeds from option exercises (in shares) 4,329   4,000          
Proceeds from option exercises $ 8 8   8        
Unrealized loss on marketable securities (2) (2)     (2)      
Foreign currency translation adjustment $ 5 5     5      
Common stock, ending balance (in shares) at Mar. 31, 2025 8,620,162   8,621,000          
Ending balance at Mar. 31, 2025 $ 25,102 $ 25,356 $ 9 $ 578,923 $ (78) $ (552,790) $ (708) $ (254)